Heron Therapeutics (HRTX) : Traders are bullish on Heron Therapeutics (HRTX) as it has outperformed the S&P 500 by a wide margin of 24.57% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.04%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.01% in the last 1 week, and is up 25.05% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Heron Therapeutics, Inc. is up 6.93% in the last 3-month period. Year-to-Date the stock performance stands at -22.02%. The stock has recorded a 20-day Moving Average of 10.32% and the 50-Day Moving Average is 14.45%.
Heron Therapeutics (NASDAQ:HRTX): The stock opened at $20.88 on Friday but the bulls could not build on the opening and the stock topped out at $20.91 for the day. The stock traded down to $20.63 during the day, due to lack of any buying support eventually closed down at $20.82 with a loss of -0.43% for the day. The stock had closed at $20.91 on the previous day. The total traded volume was 417,469 shares.
Also, Cantor Fitzgerald initiates coverage on Heron Therapeutics (NASDAQ:HRTX). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm announces the price target at $41 per share. The rating by the firm was issued on May 2, 2016.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.